Patents Assigned to Reaction Biology Corporation
  • Histone deacetylase inhibitors and methods of use thereof
    Patent number: 11155550
    Abstract: The present invention relates to methods of modulating activity of histone deacetylases (HDACs). The present invention also relates to methods of treating HDAC-associated diseases including, but not limited to, cancers, inflammatory disorders, and neurodegenerative disorders. The present invention also provides novel compounds and compositions thereof and methods of preparation of the same. The present invention also includes methods of inhibiting HDACs, and methods of treating HDAC-associated diseases using the compounds of the invention.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: October 26, 2021
    Assignee: Reaction Biology Corporation
    Inventors: Haiching Ma, Yangbo Feng, Yuren Wang
  • Inhibition of activated cdc42-associated kinase 1
    Patent number: 8658655
    Abstract: Compounds, compositions, and methods for specific inhibition of activated cdc42-associated kinase 1 (Ack1) are provided.
    Type: Grant
    Filed: March 26, 2012
    Date of Patent: February 25, 2014
    Assignees: Fox Chase Cancer Center, Reaction Biology Corporation
    Inventors: Jeffrey R. Peterson, Haiching Ma, Sean Deacon
  • INHIBITION OF ACTIVATED CDC42-ASSOCIATED KINASE 1
    Publication number: 20120245173
    Abstract: Compounds, compositions, and methods for specific inhibition of activated cdc42-associated kinase 1 (Ack1) are provided.
    Type: Application
    Filed: March 26, 2012
    Publication date: September 27, 2012
    Applicants: Reaction Biology Corporation, Fox Chase Cancer Center
    Inventors: Jeffrey R. Peterson, Haiching Ma, Sean Deacon